KU-55933 (ATM Kinase Inhibitor)

For research use only.

Catalog No.S1092

171 publications

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
USD 947 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's KU-55933 (ATM Kinase Inhibitor) has been cited by 171 publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PqNmlEPTB;Mz6yO|M2OiEQvF2= M17IN3NCVkeHUh?=
HuO-3N1 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLEeG1vUUN3ME20MlE4OTR{IN88US=> M3zabnNCVkeHUh?=
LAMA-84 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrBTXZKSzVyPUSuOVg1PjVizszN Mn7TV2FPT0WU
CAL-72 M{[yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTVwNEiwPFQh|ryP MoTvV2FPT0WU
LoVo NXixdXFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTZwOUOyN|kh|ryP NHq0ZYpUSU6JRWK=
HH MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TyTGlEPTB;OD6yO|Y4OSEQvF2= MlP2V2FPT0WU
SK-MEL-3 MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLSTGpjUUN3ME24MlI5PTd3IN88US=> MkHPV2FPT0WU
KM12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPOW4pKSzVyPUmuNlEyPDJizszN NIrDdlVUSU6JRWK=
NCI-H1437 NFXmXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17ke2lEPTB;OT64NFk4KM7:TR?= NIH4b4xUSU6JRWK=
NCI-H1838 M2nTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr0TWM2OD1zMT6xPFY2KM7:TR?= M4KzbXNCVkeHUh?=
J-RT3-T3-5 NHXESJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPMTWM2OD1zMT6yOFE4KM7:TR?= M3HoS3NCVkeHUh?=
GOTO M3HVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\rdI9xUUN3ME2xNU43QTl4IN88US=> M2\4O3NCVkeHUh?=
LB2241-RCC NXv5dnVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXEZ2tCUUN3ME2xNU44OTh4IN88US=> NGn1eo1USU6JRWK=
ES7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW0Rox2UUN3ME2xNU44QDhizszN MoD1V2FPT0WU
KP-N-YS MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K5WGlEPTB;MUKuOlM2PCEQvF2= MnnVV2FPT0WU
CAL-12T M3HaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF|Lk[xO{DPxE1? M2DTbXNCVkeHUh?=
COLO-684 NE[wPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDiXY9FUUN3ME2xOE4yPTZ7IN88US=> NVq0N2FSW0GQR1XS
DOK MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi4TGZKSzVyPUG1MlM{OjlizszN MWXTRW5ITVJ?
Hs-578-T NGjJb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF3LkSxPFIh|ryP Mnz2V2FPT0WU
D-423MG NITsPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLKRm1KSzVyPUG1MlUzOzZizszN MXfTRW5ITVJ?
DBTRG-05MG NUnxSnBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPINWM5UUN3ME2xOU43OTFzIN88US=> MlexV2FPT0WU
VM-CUB-1 MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF3Lkm4OFkh|ryP NULBfm13W0GQR1XS
KG-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnoXW5KSzVyPUG2MlA6QTZizszN NVTrNIhpW0GQR1XS
8305C M1;WWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PPbWlEPTB;MU[uNVg5QSEQvF2= M3rYVnNCVkeHUh?=
HuH-7 M3\uT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzpTWM2OD1zNj6yOlc1KM7:TR?= Mlq4V2FPT0WU
LXF-289 M3WzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF4LkK3OFch|ryP MVjTRW5ITVJ?
NCI-H1793 NHvpZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPQ[2UzUUN3ME2xOk41PzF{IN88US=> MoDPV2FPT0WU
ChaGo-K-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33ZeGlEPTB;MU[uOlU3QCEQvF2= NECyXItUSU6JRWK=
GCIY NGHLeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\hOmlEPTB;MU[uO|kxPSEQvF2= NE[xXVJUSU6JRWK=
SK-MEL-28 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj5TWM2OD1zNz6wOFc2KM7:TR?= NXLwRWpLW0GQR1XS
NCI-SNU-1 M{\mOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF5LkGyOlkh|ryP M2jo[XNCVkeHUh?=
CTB-1 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXUOllRUUN3ME2xO{4zOjV7IN88US=> NWD5eJRzW0GQR1XS
NCI-H82 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjsSphKSzVyPUG3MlQ2PzNizszN MUPTRW5ITVJ?
HCC2998 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHvTmhKSzVyPUG3MlY4OzNizszN NGjEeHpUSU6JRWK=
NCI-H2030 NX7mcnh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPp[2ZKSzVyPUG4MlE6QTdizszN MX;TRW5ITVJ?
HuP-T3 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF6LkW4PFgh|ryP Mnj6V2FPT0WU
697 NGDpWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\FTWM2OD1zOT6wNlAyKM7:TR?= NVnWcnVMW0GQR1XS
MLMA NIjoZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILMVINKSzVyPUG5MlA2PTdizszN NV3XOnN[W0GQR1XS
HCC70 NIjSZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLxTWM2OD1zOT60PFkh|ryP MlHDV2FPT0WU
A704 NETtWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPpTWM2OD1zOT64N|A2KM7:TR?= MVnTRW5ITVJ?
D-283MED M2D4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj2SlBKSzVyPUKwMlU{OzlizszN MXfTRW5ITVJ?
U031 NInmeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HYUmlEPTB;MkGuNVQ5QSEQvF2= NELiOHBUSU6JRWK=
HSC-3 M{LQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DUUWlEPTB;MkGuNVg{PSEQvF2= Ml\WV2FPT0WU
JVM-3 NHyyfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ{LkWwOkDPxE1? NYPKemhrW0GQR1XS
Mewo MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3WOG9KSzVyPUKyMlUxPzNizszN MkLGV2FPT0WU
YH-13 M37McWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTBS29KSzVyPUKyMlUyOjNizszN MULTRW5ITVJ?
LB1047-RCC M17RXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HqNWlEPTB;MkKuOVg4QSEQvF2= M4DtRnNCVkeHUh?=
HCC2157 Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDqTWM2OD1{Mj64NFU1KM7:TR?= Mny3V2FPT0WU
SNU-449 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K4UGlEPTB;MkKuPFc1QCEQvF2= Mmr5V2FPT0WU
Ramos-2G6-4C10 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vtOWlEPTB;MkKuPVYh|ryP MUDTRW5ITVJ?
CHL-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHYcYNKSzVyPUKzMlczQTJizszN NFT2dHFUSU6JRWK=
SK-MEL-30 NVrSOJVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPJXI1KSzVyPUK0MlQ3PjJizszN NGjuXGxUSU6JRWK=
PANC-08-13 NHPrbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJ3LkC5N|gh|ryP NEX4c3BUSU6JRWK=
QIMR-WIL M3nJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rkXWlEPTB;MkWuNVg2QCEQvF2= M1;IW3NCVkeHUh?=
BFTC-905 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPzWIlKSzVyPUK1MlU6PDRizszN NFnYT2VUSU6JRWK=
GI-1 NWHjVpZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjPc4JwUUN3ME2yOU44ODV3IN88US=> M333eHNCVkeHUh?=
MDA-MB-415 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG3NJE6UUN3ME2yOk42ODN|IN88US=> NHPiV29USU6JRWK=
GT3TKB NGe5T4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr6dnZKSzVyPUK2MlU{PDJizszN MoPCV2FPT0WU
DEL Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fG[mlEPTB;Mk[uPFM2PiEQvF2= M3PTc3NCVkeHUh?=
KOSC-2 NUH5NoVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ4LkmwO|Uh|ryP Ml\6V2FPT0WU
RVH-421 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr2XYhKSzVyPUK3MlI6OjFizszN NU[y[414W0GQR1XS
EW-13 NYrNbIhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHPTWM2OD1{Nz60N|A5KM7:TR?= NWXFNJd2W0GQR1XS
639-V NE\l[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXMTWM2OD1{Nz61NVE6KM7:TR?= MV7TRW5ITVJ?
A2780 M3nLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzTTWM2OD1{Nz62OFEh|ryP NGDESY1USU6JRWK=
SW982 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJ5LkmwOVIh|ryP M3XEOXNCVkeHUh?=
SW1710 M3P1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLqXJBLUUN3ME2yPE4xQThzIN88US=> Mlm1V2FPT0WU
HCC1569 Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ6LkS4PVch|ryP NVjiZZgzW0GQR1XS
MV-4-11 NWe2SXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu1TWM2OD1{OD61O|M2KM7:TR?= M1\PVXNCVkeHUh?=
BHT-101 NFnGS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jNfWlEPTB;MkiuOlU4OiEQvF2= NGTyNZNUSU6JRWK=
Ca9-22 NFe0e2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTieplKSzVyPUK4MlcyPCEQvF2= NFr6NXlUSU6JRWK=
HAL-01 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme2TWM2OD1{OD63OlE2KM7:TR?= MVzTRW5ITVJ?
D-263MG M{\0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvxTWM2OD1{OT6zOFQh|ryP NFPQfVZUSU6JRWK=
NEC8 M1fkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjFSIVrUUN3ME2yPU42PTR6IN88US=> M{OxVHNCVkeHUh?=
EKVX MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTNzLkW4OFch|ryP MkD3V2FPT0WU
EM-2 M3PY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNzLk[zNFQh|ryP MmXTV2FPT0WU
MFM-223 MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[1SXFoUUN3ME2zNU45ODl6IN88US=> M2[zNHNCVkeHUh?=
SK-PN-DW MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17QR2lEPTB;M{KuNVQxPiEQvF2= M4K4O3NCVkeHUh?=
HuO9 M4DKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LCUmlEPTB;M{KuOVI5OiEQvF2= MW\TRW5ITVJ?
MHH-PREB-1 NYPJPFRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjiVnVKSzVyPUOyMlYzOzRizszN MnPzV2FPT0WU
OVCAR-4 M33KbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\zbXVKUUN3ME2zNk45OzZ|IN88US=> Mn\1V2FPT0WU
NCI-H1648 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGzNVFMUUN3ME2zNk45PjVzIN88US=> NUfTTYJKW0GQR1XS
MKN1 NVzUVJl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;LTWM2OD1|ND6xNVAyKM7:TR?= NYjpeXR4W0GQR1XS
KYSE-450 NULXbVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELZeVJKSzVyPUO0MlY1PDRizszN Mo[yV2FPT0WU
ES8 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnFSnNzUUN3ME2zOE45QTd3IN88US=> NVPuUGxXW0GQR1XS
MS-1 M4r3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj3TlJtUUN3ME2zOE46PTV2IN88US=> M{\1W3NCVkeHUh?=
HOP-92 M3f6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnYepFKSzVyPUO1MlkzPzdizszN NWDrTo5[W0GQR1XS
SKG-IIIa MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN4LkK1OlEh|ryP MoDFV2FPT0WU
TE-11 NEfDbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXFVmdrUUN3ME2zOk42OjR|IN88US=> M3\EXXNCVkeHUh?=
SK-NEP-1 M4fsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjoTWM2OD1|Nz62O|Q1KM7:TR?= M2fteXNCVkeHUh?=
DB NIDIbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX6WY82UUN3ME2zO{46OTh3IN88US=> M2i2fHNCVkeHUh?=
IA-LM NFj0V4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXuTWM2OD1|OD6wNlM6KM7:TR?= NYDQR5dRW0GQR1XS
COLO-829 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\LcWlEPTB;M{iuOFE2QSEQvF2= MnTxV2FPT0WU
TGBC11TKB M33D[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvsTWM2OD1|OT6xOFA5KM7:TR?= Mn7PV2FPT0WU
CAL-51 NUDQSGRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33SZ2lEPTB;NECuNFYyOiEQvF2= M2Ox[3NCVkeHUh?=
NCI-H2228 NFPFSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n6SmlEPTB;NECuN|Y3OiEQvF2= NEHjdoFUSU6JRWK=
C32 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTuPItKSzVyPUSwMlQxOjRizszN MULTRW5ITVJ?
KU-19-19 NHmzS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRyLke2PFMh|ryP MXXTRW5ITVJ?
KNS-62 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr2bldLUUN3ME20NE45OzhzIN88US=> M3X0SXNCVkeHUh?=
FADU NYqwSWJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHLZnJKSzVyPUSxMlI2ODJizszN NIf5b2lUSU6JRWK=
CAL-33 NFqzfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPXZnJKSzVyPUSyMlY4PDlizszN MX\TRW5ITVJ?
CHP-134 NGXWc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\lO41KSzVyPUSyMlg1QTZizszN M{HVb3NCVkeHUh?=
HDLM-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXtcXdKSzVyPUSyMlkxQDRizszN MYXTRW5ITVJ?
NBsusSR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTR|LkC3NlUh|ryP M3GxPXNCVkeHUh?=
SW954 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR|LkGwOVMh|ryP MlfjV2FPT0WU
HCC1806 NUS0VGg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[xRZBPUUN3ME20N{41OTFizszN Mk[1V2FPT0WU
VMRC-RCZ NFKxPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorJTWM2OD12Mz60OVg3KM7:TR?= NWTTZ29nW0GQR1XS
A549 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLnWI9KSzVyPUSzMlk{OSEQvF2= MVHTRW5ITVJ?
NKM-1 NV;YbHJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR|Lkm1OVgh|ryP MYfTRW5ITVJ?
DMS-273 M{TF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnZR2hKSzVyPUS0Mlc2PjdizszN MUPTRW5ITVJ?
TYK-nu M{[xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDQTWM2OD12NT6xNlM1KM7:TR?= NHvkOJRUSU6JRWK=
KALS-1 NVTWS5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOw[FRKSzVyPUS1MlE1PiEQvF2= NUnBdmdOW0GQR1XS
A101D NX\VUoNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW2TWM2OD12NT60OFU3KM7:TR?= MY\TRW5ITVJ?
G-361 NXfKeFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzrd|l2UUN3ME20Ok4zOTN6IN88US=> M2fVfHNCVkeHUh?=
KARPAS-299 NEXxPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DqV2lEPTB;NE[uN|UyPiEQvF2= MUnTRW5ITVJ?
RS4-11 MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHETWM2OD12Nj61OFIh|ryP M2rtPHNCVkeHUh?=
HT-1376 NWXNcnJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv0O4ZKSzVyPUS2Mlc1OjZizszN NXLlNWVVW0GQR1XS
SK-N-AS NITJZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrVbmhLUUN3ME20Ok44QDJ{IN88US=> MmrsV2FPT0WU
MG-63 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3kTWM2OD12Nj65NFM3KM7:TR?= M{flfHNCVkeHUh?=
EPLC-272H MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XRS2lEPTB;NE[uPVUxOyEQvF2= MkjWV2FPT0WU
BALL-1 M1\BUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnNTWM2OD12Nz64N|Ih|ryP NHPLUYxUSU6JRWK=
LCLC-97TM1 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLBTIVwUUN3ME20PE4zODJizszN Ml\2V2FPT0WU
HO-1-N-1 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\O[2lEPTB;NEiuPVY4PiEQvF2= NH[xcFdUSU6JRWK=
MFE-280 NWLYVXY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzqcmJKSzVyPUS5MlQ3OTdizszN M4C5ZnNCVkeHUh?=
NCI-H526 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTR7LkixOlMh|ryP MmTnV2FPT0WU
D-566MG NVHkOXF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi0RXYzUUN3ME20PU46ODl4IN88US=> M3PZbHNCVkeHUh?=
BB30-HNC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLXfWE3UUN3ME20PU46PDl6IN88US=> NVHVOmV{W0GQR1XS
SK-N-DZ NYj6VIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTVyLkC0PFEh|ryP NGG5T4dUSU6JRWK=
HepG2  NGLOeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2NVcyOMLizszN MnqwNlQhcA>? MXvicI9kc3NiU1OtTWlKOy2rbnT1Z4VlKFNicHjhd4Uh[XK{ZYP0 NIjsdIozPTV{N{GyNy=>
HepG2  M3X1NWZ2dmO2aX;uJGF{e2G7 MnqzNVDDqM7:TR?= NIHRUZQzPCCq NIDzN|J{fXCycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd26|IH;mJGFVVSCxbjDT[ZIyQThzLDDDbIsyKG:wIGPldlM1PSxiQ3jrNkBwdiCWaIK2PEwh[W6mIFPkb|Ihd25iVInyNVUhcW6mdXPl[EBjgSCVQz3JTWk{ NGTyd2UzPTV{N{GyNy=>
KATO III  NXn3TnkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTTeXczNjVxNT:3MlUh|ryP MYrEUXNQ MW\lcohidmOnczD0bIUhfG:6aXPpeJkhd2Zib3zhdIFzcWJ? Mlv5NlQ5PDF5MUi=
hTCEpi MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHWWXUyOCEQvF2= NVKzV2Y6TE2VTx?= NYrTd5R3eHKndnXueJMhfGinIHP5eI9x[XSqaXOg[YZn\WO2IH;mJGhUXi1z NFKwW4YzPDN5MEizOS=>
MCF10A M2PsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;vb4kzOTBizszN MXmyOEBp NF3kXo9FVVOR MVXwc5RmdnSrYYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKEeD M{TidVI1OTVyNUm1
HL-60  M4LLTGZ2dmO2aX;uJGF{e2G7 NGrGeoQyOCEQvF2= NXjpSWlxOC53IHi= MnvBSG1UVw>? MXny[YR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjDDbIszyqB? NILMbYIzOzl|NESxNS=>
MCF-7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1THfFEuOTByzszN MoS4NlQhcA>? NYLIZ4NGTkKV M2r2TIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? NVzhSlB[OjNzOEWzOFc>
HeLa  NVnCU|I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETNV4MyNTFyMN88US=> MnPYNlQhcA>? M1e1OWZDWw>? M{PPTYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MkLpNlMyQDV|NEe=
SH-SY5Y NVPXRmx6TnWwY4Tpc44hSXO|YYm= NYrtclZNOTEEoN88UeKh NI\1Z5EzPCCq NIP0SXFqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?= Ml\DNlI3Ojd{OUS=
IMR-32 NUPtcohvTnWwY4Tpc44hSXO|YYm= NFHVSngyOMLizszNxsA> NGfYSVgzPCCq NE\4RnFqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?= MVWyNlYzPzJ7NB?=
A549 M4LPZ2Z2dmO2aX;uJGF{e2G7 M361VFExyqEQvF5CpC=> MlThNUBp NFjJUId{fXCycnXzd4V{KE6jbn:tR48ucW6mdXPl[EBxPTNiYXPjeY12dGG2aX;u MmroNlI2PTl|MkG=
T47D  NWjxbVVtTnWwY4Tpc44hSXO|YYm= MVyyNOKhdU1? MoHKNlQhcA>? Ml\HSG1UVw>? Mlj5dJJmfmWwdIOgTXIucW6mdXPl[EBl\We{YXTheIlwdiCxZjDJ{tpD|rF? NFTvR24zOTF2NEiwOS=>
A29 MEF M1zWVWZ2dmO2aX;uJGF{e2G7 M{jBUVExyqEQvF5CpC=> MXOxbC=> M17TNIJtd2Otc9MgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgZZQhW2W{NEezxsA> NGTHbG4zODB3M{e4NS=>
MDA-MB-453  NGXiUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXMPWRPPS12MDFOwG0> MYq3NkBp MXnJR|UxKG:oIEGwJO69VQ>? NHfjXYszODB3M{e4NS=>
PC-3 NW\He3E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrGZphwPS12MDFOwG0> NFj0WHM4OiCq MX3JR|UxKG:oIEGwJO69VQ>? M1q4b|IxODV|N{ix

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

- Collapse
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
3.95 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A
Smiles O=C1C=C(OC(=C1)C2=CC=CC3=C2SC4=CC=CC=C4S3)N5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID